Sjogren's syndrome is a systemic lymphoproliferative and autoimmune disease which is characterised by dryness of the eyes, mouth, and other mucous membranes. Extraglandular manifestations of Siogren's syndrome may include focal or diffuse lymphocytic and plasma cell infiltration of almost any organ.' Extraglandular lymphoid infiltrates may be found in the kidney,2 liver,3 lungs,4 muscle,5 and skin. ' There is a strong genetic component in Sjogren's. syndrome. It was one of the first autoimmune diseases in which the association with some of the HLA antigens was shown (HLA-B8 and DR3). 6 7 Nervous system disease in primary Sjogren's syndrome has been well reported.>'0 Central nervous system disease has been estimated to occur in 25%,9 and peripheral nervous system disease in approximately 10-20% of patients with primary Sjogren's syndrome.1 9 11 Some patients have a relapsing course with a cumulative neurological deficit which is indistinguishable from multiple sclerosis.'2 On the other hand, the occurrence of serious and progressive central nervous system disease in patients with Sjogren's syndrome, as suggested by the Johns Hopkins group, has been questioned in some studies. '3 14 There is evidence that nervous system disease in Sjogren's syndrome, as well as in other collagen vascular disorders, is mediated immunopathologically. 5 It has been shown in Sjogren's syndrome that inflammatory cells, predominantly mononuclear, can gain access to the nervous sysyem and its blood vessels at multiple levels. 6 Despite increasing knowledge of the different mechanisms taking part in tissue damage in collagen vascular diseases, there are still major questions to be answered. '7 Neurological manifestations were found in 56% of patients with primary or possible Sjogren's syndrome evaluated at our institution. ' The mean (SD) serum IgG value for the group with neurological complications was 19-1 (8 0) g/l v 26-3 (7 6) g/l for the group with intact nervous systems (p--0005). The serum IgG value in patients with polyneuropathy (n=7) was 16-9 (6-6) g/l, and in those with entrapment neuropathy (n=9) 15-7 (5 2) g/l. The differences were significant when compared with patients without neurological manifestations (p-*0005 and p*00005 respectively).
There were no differences in the levels of serum IgA and IgM between patients with neurological manifestations and those with intact nervous systems. (50) 2 (11) 14 (33) 61 (32) DR2 8 (33) 7 (39) 15 (36) 48 (26) DR3 15 (63) 10 (56) 25 (60) 30 (16)*** DR4 2 (8) 1 (6) 3 (7) 56 (30)** DR5
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2 (8) 3 (17) 5 (12) 19 (10) DRw6 2 (8) 1 (6) 3 (7) 49 (26) Significant differences between total patient and control groups: ***p<0001, **p<001.
the antigen DRw6 was also 7% in patients with Sjogren's syndrome and 26% in control subjects (p<O-Ol).
The only significant differences with respect to neurological manifestations were found in antigens B35 and DRI. B35 was present in 46% of patients with neurological manifestations and in 1 1% with intact nervous systems (p = 0*03). The occurrence of the antigen DRI was 50% in patients with neurological complications and 11% in those without (p=002). The p values, however, lose their significance when multiplied by the number of antigens studied.
A significant correlation was found between the presence of antibodies to SS-B and HLA-B8/DR3 antigens. B8 was found in 15/18 (83%) of patients with Sjogren's syndrome with antibodies to SS-B and in 7/24 (29%) of patients without (p-<0 001). The occurrence of the antigen DR3 in patients with Sjogren's syndrome with antibodies to SS-B was 14/17 (82%) and 11/24 (46%) in patients without antibodies to SS-B (p-<002).
Discussion
The immunological and genetic profile of Sjogren's syndrome has been defined by observation.30 31 Although one half to two thirds of patients with Sjogren's syndrome are seropositive with respect to one or more autoantibodies, a significant proportion are seronegative by standard techniques.' 32 Those who are seropositive often have hyperglobulinaemia with numerous autoantibodies, including antinuclear antibodies, rheumatoid factor, antibodies to Ro (SS-A) or La (SS-B), and circulating immune complexes :9 It has been suggested33 that patients with Sjogren's syndrome with antibodies to SS-A/ SS-B tend to have a more serious disease course than those without. On the other hand, Molina et al 3' 
